Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)
6.9300
-0.3300 (-4.55%)
NASDAQ · Last Trade: Jan 10th, 4:34 PM EST
Detailed Quote
| Previous Close | 7.260 |
|---|---|
| Open | 7.445 |
| Bid | 6.490 |
| Ask | 7.450 |
| Day's Range | 6.910 - 7.461 |
| 52 Week Range | 2.890 - 38.25 |
| Volume | 39,905 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 83,585 |
Chart
About Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)
Quantum Biopharma Ltd. is a biotechnology company focused on developing innovative therapies and treatments for a range of diseases, leveraging advanced biopharmaceutical technologies. The company specializes in creating novel drugs and biologics aimed at improving patient outcomes and addressing unmet medical needs in various therapeutic areas. Through a combination of cutting-edge research and strategic partnerships, Quantum Biopharma is actively engaged in bringing its proprietary products from the lab to clinical trials, with the ultimate goal of enhancing healthcare options and improving the quality of life for patients worldwide. Read More
News & Press Releases
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 10, 2026
NEW YORK, NY - January 10, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 10, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 9, 2026
NEW YORK, NY - January 9, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 9, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 8, 2026
NEW YORK, NY - January 8, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 8, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 7, 2026
NEW YORK, NY - January 7, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 7, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 6, 2026
NEW YORK, NY - January 6, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 6, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 5, 2026
NEW YORK, NY - January 5, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 5, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 3, 2026
NEW YORK, NY - January 3, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”)(NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 3, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 2, 2026
NEW YORK, NY - January 2, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 2, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · January 1, 2026
NEW YORK, NY - January 1, 2026 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”) (NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · January 1, 2026
NEW YORK, NY - December 31, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Canadian Imperial Bank of Commerce (“CIBC”) and Royal Bank of Canada (“RBC”), as well as their broker-dealer subsidiaries (the “Defendants”) on behalf of investors who sold the securities of Quantum Biopharma Ltd., formerly known as FSD Pharma, Inc. (“Quantum” or the “Company”)(NASDAQ: QNTM) between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”).
Via TheNewswire.com · December 31, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 31, 2025
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Completes 180-Day Toxicity Studies for Lucid-MS
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Via Investor Brand Network · December 23, 2025
Studies Will Support Investigational New Drug Application (IND) with the US FDA, Including Design of Phase 2 Trial
By Quantum BioPharma · Via GlobeNewswire · December 23, 2025
Let's have a look at the gap up and gap down stocks in today's session.
Via Chartmill · December 22, 2025
TORONTO, ONTARIO / ACCESS Newswire / December 22, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"),understands that Quantum BioPharma shareholder Paul Durkacz has filed a class action lawsuit alleging that investors in Quantum BioPharma were the victims of stock manipulation. The suit alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., were significantly and materially harmed.
Via ACCESS Newswire · December 22, 2025
TORONTO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), understands that Quantum BioPharma shareholder Paul Durkacz has filed a class action lawsuit alleging that investors in Quantum BioPharma were the victims of stock manipulation. The suit alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., were significantly and materially harmed.
By Quantum BioPharma · Via GlobeNewswire · December 22, 2025